May 2nd, 2004

Utah Company Testifies Before Congress On Malaria

Alpine, Utah. May 2, 2005. Clifton Mining Company (Clifton)(OTC:CFTN) announces William D. Moeller Chairman of Clifton and President of American Biotech Labs (ABL) was invited to testify before the Congressional House International Relations Committee, Subcommittee on Africa, Global Human Rights , and International operations. Mr. Moeller testified concerning the ability (according to three completed human studies) of ABL products to treat malaria to full recovery in an average of just 5 days.  Clifton Mining is the largest individual shareholder in ABL a private biotech company.

Malaria Major Killer of Children and Pregnant Woman

Malaria is reportedly the second leading cause of death by infection on the earth.  Estimates are that there were as much as 500 million new cases of Malaria last year.  The original drug treatments for malaria have ceased to work because of resistance.  New drugs have been developed from the sweet wormwood plant, but can not be made in large enough quantities to fill the need.  It is expected that only 30 million doses of the new drug will be available this year.  An April 22 article on the Shortfall in Malaria Drugs reported on Reuters, stated, “Some 30 million people will not get treatment and this will certainly lead to thousands of deaths”.  Malaria in Africa kills thousands of people daily, mostly children and pregnant woman.  For this reason Mr. Moeller was invited to speak.

Results Encouraging

Mr. Moeller reported that human studies had gone exceeding well, using the ASAP 10 supplement against malaria that 100% of 41 treated patients in four different hospitals and medical facilities had reached full recovery from Malaria in an average of 4-6 days.  Mr. Moeller went on to state that the biggest problem in the studies was that the patients felt so good after a few days that they failed to report back, severely limiting the number of patients reported in the final numbers.  Mr. Moeller told of how one group of 11 very ill children in Rwanda were given the ASAP 10 product in baby bottles, by a doctor to treat their Malaria.  All eleven children lived and were reported as fully recovered in less than a week.  Mr. Moeller was sad to learn that all of the other children in the medical facility, who had not received the product, had died. 

New Studies And Other Testimonies

Mr. Moeller reported that a fourth human study from a fifth medical facility in Africa had just been completed and results would be made available very soon.  He also reported that a 660 patient study had been planned but had not yet started.

Other groups who testified at the hearing included, The World Health Organization, USAID, and the Roll Back Malaria Partnership etc. For a full copy of William Moeller’s Testimony as well as those of the others please see (http://wwwc.house.gov/international_relations/afhear.htm) the government website or find the link on the main page of Clifton’s website.

Clifton trades on the U.S. OTC: (CFTN).  For additional information, contact Dr. Ken Friedman, President at 303-642-0659, and Keith Moeller Vice President at 801-756-1414 or see our website at www.cliftonmining.com

###

Note: Any statements released by Clifton Mining Company that are forward looking are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.  Editors and investors are cautioned that forward looking statements invoke risk and uncertainties that may affect the company’s business prospects and performance.